26 jun 2022
CyclomicsSeq technology was utilized in a Clinical Proof-of-Concept (CPoC) project funded by the Oncode Institute, monitoring patients with advanced head and neck cancer to distinguish between treatment responders and non-responders. The project provided promising results that pave the way for validating CyclomicsSeq in clinical practice.
Our technology, CyclomicsSeq, has been used in a recent Clinical Proof-of-Concept(Cpoc) project funded by the Oncode Institute. In this project several patients with advanced head and neck cancer were monitored over several months to obtain information about responders and non-responders for the given treatment. The project was performed in collaboration with the Netherlands Cancer Institute and the University Medical Center Utrecht.
Jeroen de Ridder says: “Based on the results obtained in this CPoC project, we were able to confidently set the next steps towards validating our technology in clinical practice. As a next step, we aim to include more patient samples to confirm these results in a larger study group.”
For more information please see: